Shares of Moderna Inc. and Merck & Co. took a sharp dive on Thursday after reports surfaced about the potential leak of clinical data for their personalized melanoma vaccine. The data, expected to be officially released this weekend, sparked significant market reactions, with Moderna's stock plummeting as much as 25% and Merck's shares dropping 3.9%.
The sudden decline in stock prices suggests that investors may have reacted negatively to the leaked information, though the specifics of the data have not been confirmed. Both companies have been highly anticipated to present the results of their joint effort in developing a personalized vaccine for melanoma, a type of skin cancer.
The market's response highlights the sensitivity of investors to any premature disclosure of critical clinical data, especially for high-profile projects. The impact on Moderna's shares was particularly severe, indicating a higher level of uncertainty or disappointment among its investors compared to Merck.